Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
On Wednesday, Guggenheim reiterated its Buy rating and $23.00 price target on Pfizer (NYSE:PFE), following the publication of an editorial in the New England Journal of Medicine by FDA CBER Director Dr. Vinay Prasad and FDA Commissioner Dr. Marty Makary. The editorial detailed a new regulatory framework for COVID-19 vaccines, advocating a shift from universal booster recommendations to a strategy focusing on high-risk populations. With a market capitalization of $132.75 billion and a healthy dividend yield of 7.31%, Pfizer remains a significant player in the pharmaceutical industry. InvestingPro analysis suggests the stock is currently undervalued, with multiple positive indicators including strong financial health and consistent dividend payments.
According to Guggenheim analyst, the policy shift is expected to have a minimal effect on Pfizer’s vaccine business. The analyst believes the new framework essentially codifies existing market trends, as COVID-19 vaccination rates have already significantly decreased since the pandemic’s peak. It is anticipated that the majority of individuals currently receiving booster shots are within the high-risk groups that will remain eligible for vaccination under the new guidelines. The company’s robust gross profit margin of 74.42% and strong revenue of $62.46 billion in the last twelve months demonstrate its operational efficiency despite market changes.
Pfizer’s antiviral treatment, Paxlovid, is seen as a potential counterbalance to any decline in vaccine usage. If vaccination rates drop, infection rates could rise, potentially leading to higher demand for antivirals like Paxlovid. The treatment, which is fully owned by Pfizer and yields higher profit margins, could benefit from this dynamic.
The analyst also noted that the regulatory change underscores the importance of Pfizer’s ongoing efforts to advance their pipeline and business development strategy. These efforts are crucial for the company to strengthen its long-term growth prospects, especially in light of the evolving landscape for COVID-19 vaccine recommendations and usage.
In other recent news, Pfizer Inc. has entered into a significant licensing agreement with 3SBio for the compound SSGJ-707, a PD-1/VEGF inhibitor, for an upfront payment of $1.25 billion and potential milestone payments nearing $5 billion. This move is expected to strengthen Pfizer’s position in the oncology market, particularly in cancer immunotherapy. Analysts from Jefferies have raised Pfizer’s stock target to $33, maintaining a Buy rating, while Bernstein and Cantor Fitzgerald have maintained their ratings at Market Perform with a $30 target and Neutral with a $24 target, respectively. The deal has sparked discussions regarding Pfizer’s collaboration with Summit Therapeutics (NASDAQ:SMMT), though Pfizer has stated that the existing agreement remains unchanged.
Furthermore, the U.S. Food and Drug Administration (FDA) has announced new requirements for clinical trials for COVID-19 booster shots for healthy individuals under 65. This decision could impact vaccine manufacturers like Pfizer, as they may need to conduct additional trials to gain approval for annual shots for younger populations. Meanwhile, CLSA has raised 3SBio’s stock target to HK$19.60, citing the partnership with Pfizer as a significant milestone. The collaboration is anticipated to enhance 3SBio’s market presence and future revenue streams.
These developments reflect Pfizer’s strategic efforts to expand its oncology portfolio and navigate regulatory challenges in the COVID-19 vaccine landscape. Investors will be keenly observing how these initiatives impact Pfizer’s financial performance and market position in the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.